Slingshot members are tracking this event:
FDA and EMA Accept for Review Biogen's (BIIB) Marketing Application for Nusinersen in Treatment of Spinal Muscular Atrophy (SMA)
Slingshot Insights Explained
Oct 28, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Ema, European Medicines Agency, Spinal Muscular Atrophy, Sma, Nusinersen, Priority Review, Marketing Authorization Application, Accelerated Assessment, Chmp